Compare Expedia Group Inc (EXPE) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Expedia Group Inc vs Pfizer Inc — how do they compare? Expedia Group Inc trades at $269.5 (market cap $31.07B), while Pfizer Inc trades at $27.75 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 5.1× Expedia Group Inc's market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Expedia Group Inc for 48 Days and Pfizer Inc for 158 Days on average.
| EXPE | PFE | |
|---|---|---|
Market Cap | $31.07B | $159.59B |
Volume | 1,305,431 | 30,937,010 |
Sector | Consumer Cyclical | Health |
52-Week High | $339.13 | $29.02 |
52-Week Low | $188.51 | $23.67 |
Typical Hold Time | 48 Days | 158 Days |
Enterprise Value | $29.63B | $211.09B |
Dividend Yield | 0.74% | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Expedia Group (EXPE) trades at $270.13, up 3.95% today, with strong earnings beats in recent quarters but facing technical bearish signals. The company shows robust fundamentals with 2025 revenue of $14.73B, net income of $1.29B, and healthy cash flow generation. Recent news highlights competitive threats from AI travel agents and workforce reductions, while analyst consensus remains mixed with a $335.06 price target.
EXPE presents a valuation opportunity with P/E of 16.28 below sector averages, but faces significant headwinds from AI disruption in travel booking. The stock's 199% ROE and consistent earnings outperformance support long-term growth potential, though near-term technical weakness and competitive pressures require careful monitoring.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Expedia Group Inc
Expedia is the world's largest online travel agency by bookings, offering services for lodging (75% of total 2021 sales), air tickets (3%), rental cars, cruises, in-destination, and other (15%), and advertising revenue (7%). Expedia operates a number of branded travel booking sites, including Expedia.com, Hotels.com, Travelocity, Orbitz, Wotif, AirAsia, and Vrbo. It has also expanded into travel media with the acquisition of Trivago. Transaction fees for online bookings account for the bulk of sales and profits.
Read more on EXPE →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
